The nanocarrier in the presented study was targeted towards PSMA, a 100 kDa type II membrane glycoprotein, highly expressed on almost all prostate cancer cells37 or endothelial cells of tumor vasculature of many non-prostatic solid malignancies but not on healthy cells38. This evidence concerns the gene FOLH1 and prostate carcinoma.